| Product |
Cat# |
IFU |
Incubation |
Std.Range/Sensibil. |
Specimen |
Type |
Method |
Units |
| PSA, free IRMA |
RIA4896 |
|
120 min. |
0.3 - 30 ng/ml /// 0.02 ng/mL |
200 ul serum, plasma |
CT IRMA |
I125 |
50 tubes |
| PSA, total IRMA |
RIA4895 |
IFU |
120 min |
1-100 ng/ml /// 0.2 ng/mL |
100 ul serum, plasma |
CT Irma |
I125 |
100 tubes |
| CA 125 Irma |
RIA4438 |
IFU |
120 / 60 min |
4,8 - 786 U/ml // 0,7 U/ml |
100 uL serum |
CT |
I125 |
48 tests |
| CA 15-3 Irma |
RIA4426 |
IFU |
90 / 90 min. |
2,86 - 331.0 U/ml // 0,33 U/ml |
50 ul serum |
CT |
I125 |
48 tests |
| NSE Irma |
RIA4411 |
IFU |
120 min. |
2,5 - 270 ng/ml // 0.1 ng/ml |
50 ul serum |
CT |
l125 |
96 test |
| AFP Irma (cubic size) |
RIA4385 |
IFU |
60 / 60 min. at RT |
5.3 - 440.0 IU/ml // 0.5 IU/ml. |
50 ul serum or plasma |
Irma |
I125 |
4 x 96 tests |
| CEA Irma |
RIA4384 |
IFU |
2 hrs. at 37 C |
2 - 200 ng/ml // 0.17 ng/ml |
100 ul serum or plasma |
Irma |
I125 |
96 tests |
| AFP Irma |
RIA4368 |
IFU |
60 / 60 min at RT |
5.3-440.0 IU/ml // 0.5 IU/ml. |
50 ul serum or plasma |
Irma |
I125 |
96 tests |
| Cyfra 21-1 |
RIA3937 |
IFU |
20h RT |
3-40 ng/ml |
100 ul serum |
CT Beads |
I125 |
100 tests |
| CA 72-4 |
RIA3936 |
IFU |
4h 37C / 18h 2-8C |
3-100 U/ml |
100 ul serum, plasma |
CT Beads |
I125 |
100 tests |
| CA 15-3 |
RIA3935 |
IFU |
2h RT/3h RT |
25-200 U/ml / 1.4 U/ml |
20 ul serum, plasma |
CT Beads |
I125 |
100 tests |
| CA 19-9 |
RIA3934 |
IFU |
3h 37degr./3h RT |
15-240 U/ml / 1.4 U/ml |
100 ul serum, plasma |
CT Beads |
I125 |
100 tests |
| CA 125 II |
RIA3933 |
IFU |
20h (RT) |
15-500 U/ml / 0.4 U/ml |
100 ul serum |
CT Beads |
I125 |
100 tests |
| NSE (Neuron specific Enolase) RIA |
RIA3665 |
IFU |
|
|
|
Irma |
I125 |
96 tests |
| TPS (CYK18) (Tissue Polypeptide Specific Ag) (Cytokeratin) Irma |
RIA3028 |
IFU |
|
|
|
Irma |
I125 |
100 tests |
| Occult Detect Advanced Rapid Test (cassette) (min 10 kits) |
RAP4723 |
IFU |
8 min. |
- // 40 ng/ml Hemoglobin |
stool |
qualitative |
cassette |
12 cass |
| Occult Detect Eco-Pro Rapid Test (dipstick) (min 10 kits) |
RAP4721 |
IFU |
10 min |
- /// 50 ng/ml Haemoglobin |
stool |
quantitative |
dipstick |
25 tests |
| Occult Detect |
RAP4236 |
IFU |
5 - 10 min. |
qualitative // 50 ng hHb/ml |
stool |
qualitative |
cassette |
20 cass. |
| PSA semiquantitative (cassette) |
RAP3539 |
IFU |
|
|
|
semiquantitative |
cassette |
each |
| Cripto-1 Elisa |
EIA5109 |
IFU |
180/30/20 min. |
50-800pg/ml /// 8.4 pg/ml |
50 ul serum |
quantitative |
MTPL |
96 wells |
| Cyr 61 Elisa |
EIA5108 |
IFU |
120/30/15 min. |
400-1000pg/ml /// 19.4 pg/ml |
50 ul serum, plasma (EDTA, Hepar |
quantitative |
MTPL |
96 wells |
| TM-CYFRA21.1 |
EIA5070 |
IFU |
60 / 15 min |
3 - 50 ng/ml /// 0.15 ng/ml |
50 ul serum, plasma |
quantitative |
MTPL |
96 wells |
| NSE Elisa (controls included) |
EIA4610 |
IFU |
60 / 15 min |
4 - 100 ng/mL // 4 ng/mL. |
25 uL serum |
quantitative |
MTPL |
96 wells |
| CA-242 Elisa - Pancreatic-colo-rectal - (no controls incuded) |
EIA4581 |
IFU |
120 / 60 / 30 min. |
5 - 200 U/ml // 1 U/ml |
25 ul serum |
quantitative |
MTPL |
96 wells |
| p27, human p27 (p27Klp1) |
EIA4491 |
IFU |
609/60/30/30 min |
25 - 1,600 pg/mL // 10.8 pg/mL |
100 uL total cell lysates |
quantitative |
MTPL |
96 wells |
| Bcl-2, human Bcl-2 Elisa (B-cell lymphoma 2) |
EIA4488 |
IFU |
60/60/30/30 min |
18.8 - 1,200 pg/mL // 3.8 pg/mL |
100 uL total cell lysates |
quantitative |
MTPL |
96 wells |
| Bax, human Bax Elisa, (Bcl1 associated x protein) |
EIA4487 |
IFU |
60 /60/30/30 min |
62.5 - 2,000 pg/mL // 10.1 pg/mL |
10 uL total cell lysates |
quantitative |
MTPL |
96 wells |
| NSE |
EIA4424 |
IFU |
60 / 30 min |
5 - 200 ug/L // 1ug/L |
25 uL serum |
quantitative |
MTPL |
96 wells |
| PSA free |
EIA4189 |
IFU |
60/60/15 min |
0.75 - 12 ng/ml / 0.1 nng/ml |
25ul serum |
quantitative |
MTPL |
96 wells |
| Survivin (total) human |
EIA4137 |
IFU |
60/60/30/30 min. RT |
31.25-1,000 pg/mL // 10.4 pg/mL |
100 uL biolog. fluids |
|
|
96 wells |
| PSA, Total |
EIA3945 |
|
|
|
|
quantitative |
MTPL |
96 wells |
| Cyfra 21-1 Elisa |
EIA3943 |
IFU |
30 / 30 min |
3 - 50 ng/ml // <0.266 ng/ml |
50 ul serum/plasma |
quantitative |
MTPL |
96 wells |
| CA 72-4 |
EIA3942 |
IFU |
120/30 min. |
3-100 U/ml // < 0.311 |
20 ul serum, plasma |
quantitative |
MTPL |
96 wells |
| CA 15-3 |
EIA3941 |
IFU |
60/30/30 min |
25-200 U/ml // 0.905 U/ml |
10 ul serum, plasma |
quantitative |
MTPL |
96 wells |
| CA 19-9 |
EIA3940 |
IFU |
30 / 30 min |
15-240 U/ml / 0.888 U/ml |
10 ul serum, plasma |
quantitative |
MTPL |
96 wells |
| CA 125 |
EIA3939 |
IFU |
50 / 30 min |
15 - 200 U/ml // 3.327 U/ml |
50 ul serum, plasma |
quantitative |
MTPL |
96 wells |
| PAP Complex (Plasmin alpha-2 Antiplasmin Complex) |
EIA3763 |
IFU |
20'/20'/15' |
50 - 5000 ug/l / 50 ug/l |
plasma 50 ul |
quantitative |
MTPL |
192 wells |
| PSA total |
EIA3719 |
IFU |
1.5 hrs |
1.56 - 25 ng/ml / 0.5 ng/ml |
25 ul |
quantitative |
MTPL |
96 wells |
| UBC (Urinary Bladder Cancer) Elisa |
EIA2355 |
IFU |
|
|
urine |
quantitative |
MTPL |
96 wells |
| TPS (CYK18) (Tissue Polypeptide Specific Ag) (Cytokeratin) Elisa |
EIA2354 |
IFU |
|
|
|
quantitative |
MTPL |
96 wells |
| NSE (Neuron specific Enolase) (controls to be ordered extra EIA4458) |
EIA2353 |
IFU |
|
|
|
quantitative |
MTPL |
96 wells |
| CEA |
EIA1871 |
IFU |
80 min. at RT |
1.0 ng/ml |
serum |
quantitative |
MTPL |
96 wells |
| CEA |
EIA1868 |
IFU |
60 / 15 min. |
0 - 100 ng/ml // 0.44 ng/ml |
50 ul serum / plasma |
quantitative |
MTPL |
96 wells |
| PSA free |
EIA1792 |
IFU |
2 hrs. at RT |
0.05 ng/ml |
serum |
quantitative |
MTPL |
96 wells |
| PAP (Prostatic Acid Phosphate) |
EIA1566 |
IFU |
40 min at RT |
1-30 ng/ml |
serum |
quantitative |
MTPL |
96 wells |
| CA 19-9 (Gastrointestinal Cancer) Antigen (GCA) |
EIA1474 |
IFU |
120 min. at 37 C. |
5 U/ml |
serum |
quantitative |
MTPL |
96 wells |
| CA 15-3 (Breast Cancer) Antigen (BCA) |
EIA1473 |
IFU |
120 min. at 37 C. |
5 U/ml |
serum |
quantitative |
MTPL |
96 wells |
| CA 125 (Ovarian Cancer) Antigen |
EIA1472 |
IFU |
3 hrs. at 37 C. |
5 U/ml |
serum |
quantitative |
MTPL |
96 wells |
| Cyfra 21-1 |
CLA4731 |
IFU |
30 min. |
3 - 50 ng/ml /// 0.03 ng/ml |
50 ul serum, heparin plasma |
qualitative |
MTPL |
96 wells |
| CA 72-4 |
CLA4730 |
IFU |
|
|
|
quantitative |
MTPL |
96 wells |